Related Experiment Video
Updated: Nov 16, 2025
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
Cannabinoids in glioblastoma multiforme-hype or hope?
Gary J Doherty1,2, Bruno H R de Paula3,4,5
1Department of Oncology, Cambridge University Hospitals NHS Foundation, Trust, Cambridge Biomedical Campus, Cambridge, UK. gd231@cam.ac.uk.
Abstract:
Cannabis and its derivatives are being used increasingly by patients with cancer, including patients with glioblastoma multiforme (GBM), the most common and aggressive primary brain malignancy. Despite promising preclinical data suggesting potential anti-cancer effects for cannabinoids in GBM, clinical and safety data are lacking. This editorial will discuss a recent Phase 1b trial of nabiximols oromucosal spray in combination with dose-intense temozolomide in patients with recurrent GBM in the context of other relevant findings in this field.
Insights
Cannabis derivatives show potential against glioblastoma multiforme (GBM), but clinical data is limited. A Phase 1b trial explored nabiximols with temozolomide in recurrent GBM patients.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- Increasing use of cannabis derivatives in cancer care, particularly for glioblastoma multiforme (GBM).
- Preclinical studies suggest cannabinoids possess anti-cancer properties relevant to GBM.
- Lack of robust clinical and safety data for cannabinoid use in GBM patients.
Discussion:
- Focus on a Phase 1b trial evaluating nabiximols oromucosal spray combined with dose-intense temozolomide.
- Contextualizes trial findings within existing research on cannabinoids and GBM.
- Addresses the clinical application and safety profile of this combination therapy.
Key Insights:
- Highlights the need for more clinical evidence on cannabis-based therapies in oncology.
- Emphasizes the potential therapeutic role of cannabinoids in aggressive brain tumors like GBM.
- Underscores the importance of evaluating drug combinations for recurrent GBM treatment.
Outlook:
- Further clinical trials are necessary to establish efficacy and safety of nabiximols in GBM.
- Exploration of cannabinoid mechanisms in brain tumor models warrants continued investigation.
- Potential for novel therapeutic strategies combining cannabinoids with standard chemotherapy.
